Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 99 systematic review(s)/meta-analysis(es). ^[1-98]
• Adalimumab improved Psoriasis Area and Severity Index (PASI) 75 (odds ratio (OR) = 4.50; 95% confidence interval (CI) = 2.81-7.22; P < .00001) and Physician's Global Assessment (PGA) 0/1 response (OR = 4.86; 95% CI = 3.02-7.82; P < .00001) in psoriasis, with improvement in PASI 100 (OR = 3.01; 95% CI = 1.33-6.80; P = .008) but no significant impact on PASI 90 (OR = 3.30; 95% CI = 0.77-14.20; P = .11).
• For severe ulcerative colitis, adalimumab showed mucosal healing effectiveness of 75.40%, clinical remission at 70.79%, and clinical response at 83.02%, with highest effectiveness achieved at a 40 mg dose over 52 weeks.
• In pediatric Crohn’s disease, adalimumab achieved induction of remission in 59%, induction of response in 60%, maintenance of remission in 57%, and maintenance of response in 63%.
• In rheumatoid arthritis, tofacitinib, low-dose decernotinib, and high-dose peficitinib demonstrated significant increases in American College of Rheumatology (ACR) 20/50/70 compared to adalimumab as a control.
• No significant impact on adverse events (OR = 1.23; 95% CI = 0.26-5.87; P = .79) or serious adverse events (OR = 2.59; 95% CI = 0.49-13.79; P = .26) between adalimumab and methotrexate in psoriasis.
• No significant difference in serious adverse event incidence rates between adalimumab biosimilar agents and reference agents at 16, 24, and 51 weeks.
• Higher overall adverse events associated with infliximab in ulcerative colitis; no significant difference in serious adverse events between adalimumab and infliximab.
• In pediatric Crohn’s disease, serious adverse events varied, though generally not severe.
• For ulcerative colitis, patient age, disease duration, and gender were considered, with the highest effectiveness observed with a 40 mg dose over 52 weeks; no subgroup-specific differences in effectiveness were reported.
• In dermatology clinical trials, non-white individuals showed no significant population-based outcome differences across treatment groups.